Skip to content
Business Segments · Total other segment expense, net

Oncology & Multispecialty — Total other segment expense, net

McKesson Oncology & Multispecialty — Total other segment expense, net remained flat by 0.0% to $11.82B in Q4 2026 compared to the prior quarter. Year-over-year, this metric declined by 7.0%, from $12.71B to $11.82B. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ3 2024
Last reportedQ4 2026May 8, 2026

How to read this metric

An increase in net expenses suggests rising overhead or non-core costs, while a decrease indicates improved cost management or higher non-operating income.

Detailed definition

Represents the net of miscellaneous operating expenses and income items not directly attributable to core segment operat...

Peer comparison

Similar to 'Other Operating Expenses' or 'Unallocated Segment Costs' found in the segment reporting of other large pharmaceutical distributors.

Metric ID: mck_segment_oncology_multispecialty_total_other_segment_expense_net

Historical Data

8 periods
 Q3 '24Q4 '24Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Value$8.96B$9.29B$11.71B$12.71B$11.82B$11.82B$11.82B$11.82B
QoQ Change+3.7%+26.1%+8.5%-7.0%+0.0%+0.0%+0.0%
YoY Change+30.8%+36.8%+0.9%-7.0%
Range$8.96B$12.71B
CAGR+17.2%
Avg YoY Growth+15.4%
Median YoY Growth+15.8%
Current Streak3 quarters growth

Frequently Asked Questions

What is McKesson's oncology & multispecialty — total other segment expense, net?
McKesson (MCK) reported oncology & multispecialty — total other segment expense, net of $11.82B in Q4 2026.
How has McKesson's oncology & multispecialty — total other segment expense, net changed year-over-year?
McKesson's oncology & multispecialty — total other segment expense, net decreased by 7.0% year-over-year, from $12.71B to $11.82B.
What does oncology & multispecialty — total other segment expense, net mean?
The net total of miscellaneous operating expenses and income items for the Oncology and Multispecialty segment.